NCT00222144

Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer

Phase II Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: University of Kansas · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment.

Detailed description

The purpose of this study is to evaluate the response rate of Gleevec with Taxotere in patients with recurrent non-small cell lung cancer. Also to determine the expression of PDGF-R, phosphorylated PDGF-r and C-kit in the original tissue and correlate with response. If the patient has a tumor in an accessible location, we will ask for consent from the patient to obtain biopsy before and after the therapy to assess the same molecular markers.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Gleevec and Taxotere	Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15

Timeline

• Start date: 2004-09-01
• Primary completion: 2010-11-01
• Completion: 2010-11-01
• First posted: 2005-09-22
• Last updated: 2012-08-07

Locations

2 sites across 1 country: United States